2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
21
Dermatologic
17
Thoracic
13
Genitourinary
6
Sarcoma
5
Head & Neck
4
Gynecologic
3
Other solid neoplasm
2
Lymphoid
2
Breast
2
Plasma cell
1
Endocrine
1
Conditions
Advanced Solid Tumors
483
Solid Tumor
446
Advanced Solid Tumor
414
Unspecified Adult Solid Tumor, Protocol Specific
362
Solid Tumors
336
Mesothelioma, Malignant
324
Mesothelioma
289
Solid Tumor, Adult
124
Carcinoma, Non-Small-Cell Lung
122
Retinoblastoma
117
Lung Neoplasms
77
Ovarian Neoplasms
75
Melanoma
65
Sarcoma
62
Carcinoma, Renal Cell
59
Stomach Neoplasms
58
Pancreatic Neoplasms
58
Neoplasms
53
Esophageal Neoplasms
53
Small Cell Lung Carcinoma
52
Colorectal Neoplasms
52
Hematopoietic and Lymphatic System Neoplasm
50
Uterine Cervical Neoplasms
46
Breast Neoplasms
46
Solid Tumours
35
Neoplasm Metastasis
35
Advanced or Metastatic Solid Tumors
35
Squamous Cell Carcinoma of Head and Neck
34
Carcinoma, Hepatocellular
32
Triple Negative Breast Neoplasms
31
Interventions
tremelimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Diabetes Mellitus, Insulin-Dependent, 12
×
Other solid neoplasm
×
Clear all
NCT01843374
2026-03-05
Tremelimumab
MedImmune LLC
Phase 2
Active not recruiting
571 enrolled
19 charts
NCT04631731
2023-06-01
ICEMELT
Western Sydney Local Health District
Phase 1/2
Unknown
200 enrolled